Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ArriVent BioPharma, Inc. ( (AVBP) ) has provided an announcement.
On January 21, 2025, ArriVent BioPharma, Inc. entered into an exclusive license agreement with Lepu Biopharma Co., Ltd. to develop and commercialize MRG007, an antibody-drug conjugate for gastrointestinal cancers, outside of Greater China. This agreement entitles Lepu Biopharma to $47 million in upfront and milestone payments and potential additional payments based on development, regulatory, and sales milestones. This strategic move expands ArriVent’s pipeline and strengthens its position in the oncology market by potentially offering a new treatment for gastrointestinal cancers globally.
More about ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative therapeutics to address unmet medical needs in cancer treatment. The company aims to leverage its drug development expertise to advance its pipeline of novel therapeutics, including next-generation antibody drug conjugates.
YTD Price Performance: -7.86%
Average Trading Volume: 152,261
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $852.9M
Find detailed analytics on AVBP stock on TipRanks’ Stock Analysis page.
